BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pollinex Quattro Complete Grass regulatory update

Allergy Therapeutics submitted a response to questions from Germany's Paul Ehrlich Institute for an MAA for Pollinex Quattro Complete Grass to treat grass pollen allergies. In June, the agency requested information on the quality and CMC sections of the application, but did not request additional clinical trials. The MAA was submitted under the EU Mutual Recognition Procedure. The product is a subcutaneous grass pollen allergy vaccine formulated with allergoids, tyrosine plus the toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >